Drug development programs tend to fail as they progress from preclinical to clinical stages, due to risks that are not addressed early. These risks often include incomplete preclinical validation, overlooked intellectual property (IP), regulatory misalignment and late-stage manufacturing challenges. A proactive, structured approach to de-risking drug development can reduce delays, control costs and improve the likelihood of clinical and commercial success.
In a recent webinar with BioSpace, our Chief Scientific Officer, Sir Michael Houghton, Chief Translational Officer, Launa Aspeslet, and Executive Scientists Daren Ure and Daniel Trepanier, discussed how innovators can advance early proof-of-concept to the clinic using lean, cost-effective approaches that help de-risk drug development.
Our experts outline three practical strategies to reduce risk early and improve the likelihood of clinical success:
1. Prioritize Early Validation in Drug Development
“It’s never too early for developers to consider how to translate research to the clinic. They must consider the type of proof-of-concept data to support this translation.”
Sir Michael Houghton, Chief Scientific Officer at API
Early validation is a critical step in de-risking drug development, ensuring that research is designed with clinical translation in mind from the outset. By prioritizing early validation, developers can reduce risk, avoid delays and minimize costly downstream failures when moving from preclinical to clinical stages.
A structured, de-risked validation approach leads teams to making more informed, cost-effective decisions early in the drug development process.
Key considerations for early validation in drug development:
- Adopt a de-risked drug development pathway. Most drug development failures happen because risks are identified too late. Bringing the right experts in early helps teams proactively identify challenges, select stronger lead candidates and reduce failure rates. Overall, Ure explained that it ensures consistent mechanism-of-action evidence, potency, safety, selectivity, pharmacokinetic (PK) profile and drug interactions, evaluated from biochemical binding through cells to animal models.
- Use AI and computational tools. AI tools can help filter large discovery libraries into smaller, more viable candidate sets, improving efficiency early in development. “Although AI has not yet delivered a single perfect molecule without further experimentation, it is already accelerating early-stage decision-making,” Ure said.
- Map a clinical development plan. “Establishing a clinical development plan at the very start helps align preclinical models with the target clinical trial population,” Houghton said. This includes identifying biomarkers and surrogate endpoints, and ensuring scalable manufacturing and realistic formulation timelines.
2. Implement an IP and regulatory strategy from the start
Integrating an intellectual property (IP) and regulatory strategy early is essential to de-risk drug development and ensure innovations are both protected and compliant within realistic timelines.
By aligning IP and regulatory considerations from the beginning, developers can avoid common pitfalls that often delay or derail progress from preclinical to clinical stages. Without an early strategy in place, companies risk:
- Weaker IP protection and reduced commercial exclusivity
- Misaligned development plans that require costly rework
- Regulatory delays that slow time to market
- A shortened commercial window for their drug candidate
Taking a proactive approach to IP and regulatory planning helps streamline development, reduce uncertainty and support a faster, more efficient path to commercialization.
Key considerations for IP and regulatory risk management:
- Optimize discovery timelines within patent constraints. Drug development timelines are closely tied to the patent lifecycle, making it necessary to manage discovery efficiently. Optimizing early timelines helps preserve commercial exclusivity and supports a faster timeline path.
“Discovery plus preclinical and Phases 1–3 typically must fit into an approximately 10 to 13-year timeframe, so discovery cannot drag on continuously.”
Daniel Trepanier, Executive Scientist, Preclinal Development at API
- Implement a parallel IP approach. Delays in development can reduce a drug’s commercial window. A parallel intellectual property (IP) strategy – balancing early patent filings with careful management of disclosures – helps protect innovation while maintaining momentum. Trepanier recommended using simple early formulations through IND-enabling studies and early clinical trials, while developing more advanced, patentable formulations in parallel.
- Engage regulators early: “Regulatory requirements should be considered through the translational and early clinical processes,” Aspeslet said. Ongoing communication with regulators can support adaptive trial designs, rolling submissions and supportive nonclinical or external data. Houghton and Ure added that developers should review guidance for their specific modalities to understand regulatory nuances.
- Establish a clear go/no-go decision criteria: Defining clear go/no-go decision points helps keep IP and regulatory strategies focused on the most promising drug candidates. Establishing these benchmarks early allows teams to avoid sunk cost traps, reduce unnecessary spending and make more strategic decisions throughout the development process.
3. Plan for scalable manufacturing early
Early manufacturing decisions help determine product scalability and long-term efficiency. “Even at the earliest stage, future manufacturing should be eyed,” Trepanier said. Developers should design synthetic routes with scalability in mind – this will lead to:
- Fewer steps
- Higher yields
- Stable drug substances
- Accessible reagents that are not vulnerable to political supply shocks
A strategic approach for selecting a CDMO is crucial to avoid costly corrections later. Including this in your manufacturing considerations will help reduce risk and support a smoother path to scale-up.
Key Takeaways
Many drug development programs fail during the transition from preclinical to clinical stages – not because the science is flawed, but because key risks are not addressed early. The most common issues include weak preclinical validation, overlooked intellectual property (IP), regulatory misalignment and late-stage manufacturing challenges. To overcome these hurdles, experts recommend a proactive, structured approach focused on three core areas.
- Early validation ensures research is designed with clinical translation in mind, enabling better decision-making and reducing costly downstream failures.
- Integrating IP and regulatory strategy early helps protect innovation, avoid delays, and maintain commercial viability by aligning development with patent timelines and regulatory expectations.
- Planning for scalable manufacturing from the outset ensures processes can transition efficiently to larger-scale production, avoiding rework and supply challenges later.
Get Connected
Looking to reduce risk and accelerate your drug development program?
Connect with API’s team to explore how integrated scientific, regulatory, and manufacturing expertise can support your path to clinic.
Book a discovery call